Treatment Success With the CoolLoop Cryoablation System

NCT ID: NCT03818724

Last Updated: 2022-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-17

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study evaluates the safety and efficacy of the treatment with the CoolLoop® cryoablation System (sclerotherapy of muscle tissue of the heart by freezing) in patients with atrial fibrillation (permanent atrial fibrillation excepted) over a follow-up period of 36 months.

A further aim of this study is to evaluate the average duration of procedure and fluoroscopy times.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Paroxysmal Atrial Fibrillation Persistent Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CoolLoop® cryoablation system

Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system

CoolLoop® cryoablation system

Intervention Type DEVICE

Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CoolLoop® cryoablation system

Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* atrial fibrillation: permanent AF excepted
* ECG documented AF within the last 6 months
* patients planned for an ablation procedure and suitable and planned for treatment with the CoolLoop® cryoablation system
* signed and dated informed consent documented by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment (patient has received a copy of the ICF)

Exclusion Criteria

* indication that the vascular system is not accessible through the left or right groin.
* indication that a transseptal puncture cannot be performed.
* any previous ablation or surgery due to AF.
* important comorbidities such as cardiovascular events within six months of enrollment or high-risk surgical patients.
* pregnant women at the time of the cryoablation procedure.
* any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the Informed Consent Form.
* participation in interventional trials for cardiovascular devices or drugs.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Raffeiner GmbH

INDUSTRY

Sponsor Role collaborator

afreeze GmbH

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Kaiser, PhD

Role: STUDY_DIRECTOR

afreeze GmbH

Florian Hintringer, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University Innsbruck

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University Innsbruck

Innsbruck, Tirol/Austria, Austria

Site Status RECRUITING

Marienhaus Klinikum St. Elisabeth Neuwied

Neuwied, Germany/Rheinland-Pfalz, Germany

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andreas Kaiser, PhD

Role: CONTACT

+43 (0) 69911073109

afreeze GmbH

Role: CONTACT

+43 (0) 512 209012 ext. 0

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Florian Hintringer, MD

Role: primary

Burkhard Hügl, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CooL-TreatS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Medtronic Terminate AF Study
NCT03546374 RECRUITING NA
FREEZE-AFIB Post-Market Study
NCT05089877 COMPLETED